Get the Stockscreener App
2.94
3.29%
-0.10
After Hours:
2.95
0.01
+0.34%
Immunitybio Inc stock is traded at $2.94, with a volume of 11.66M.
It is down -3.29% in the last 24 hours and up +3.89% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$3.04
Open:
$3.2
24h Volume:
11.66M
Relative Volume:
1.67
Market Cap:
$2.15B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-3.0309
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+21.49%
1M Performance:
+3.89%
6M Performance:
-52.04%
1Y Performance:
-19.45%
1-Day Range:
$2.93
$3.30
1-Week Range:
$2.28
$3.30
52-Week Range:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.94 | 2.15B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Why Did Immunitybio (IBRX) Go Down on Friday? - MSN
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Insider Monkey
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - MSN
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpStill a Buy? - MarketBeat
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2%What's Next? - MarketBeat
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.3%Here's Why - MarketBeat
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - Insider Monkey
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
ImmunityBio stock gains 15% amid regulatory updates (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances - MarketWatch
ImmunityBio shares surge following progress in FDA discussions By Investing.com - Investing.com Canada
ImmunityBio shares surge following progress in FDA discussions - Investing.com
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Benzinga
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - BioSpace
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - BioSpace
How to spot and prevent hypothermia - AOL
Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 5.2%Time to Sell? - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Sets New 12-Month LowHere's What Happened - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies By Investing.com - Investing.com South Africa
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio gains unique J-code for bladder cancer treatment - Investing.com
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective - The Bakersfield Californian
As ImmunityBio's Bladder Cancer Drug Gains Ground, Will The Stock Pick Up Steam? - RTTNews
ImmunityBio (NASDAQ:IBRX) Trading 7% HigherHere's What Happened - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Barclays PLC - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Up 2.6%Time to Buy? - MarketBeat
IBRX Stock Hits 52-Week Low at $2.6 Amid Market Challenges - Investing.com
5 Companies That Celebrated First Approvals in 2024 - BioSpace
State Street Corp Purchases 790,408 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):